Skip to main content

Drug Interactions between leniolisib and sars-cov-2 (covid-19) chadox1 vaccine, recombinant

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

SARS-CoV-2 (COVID-19) ChAdOx1 vaccine, recombinant leniolisib

Applies to: sars-cov-2 (covid-19) chadox1 vaccine, recombinant and leniolisib

MONITOR: The administration of live, attenuated vaccines to patients receiving therapy with leniolisib has not been studied but may be associated with diminished or suboptimal immunologic response. Patients with activated phosphoinositide 3-kinase delta (APDS) are reported to have reduced humoral and cellular immunity. A retrospective cohort study of the clinical and laboratory features of eight patients with activated phosphoinositide 3-kinase delta (APDS) reported that all patients received vaccination with both attenuated live and subunit vaccines with no adverse effects, with some displaying an impaired vaccination response. However, the clinical trial evaluating the efficacy of leniolisib in patients with APDS-associated genetic PI3K-delta mutation with a documented variant in either PIK3CD or PIK3R1 excluded patients who had received live vaccines (including attenuated live vaccines) in the 6-week period prior to study entry and for up to 7 days after receiving the last dose of leniolisib. Data concerning administration of inactivated, killed, or otherwise noninfectious vaccines are not available.

MANAGEMENT: Due to the potential for a diminished or suboptimal immunologic response, caution is recommended with the administration of live, attenuated vaccines in patients receiving therapy with leniolisib. Specific recommendations concerning the administration time of live, attenuated vaccines in relation to leniolisib therapy are not available. Although there is no data concerning the use of inactivated, killed, or otherwise noninfectious vaccines, caution is also advised. Local immunization guidelines and prescribing information for individual vaccines and leniolisib should be consulted for further guidance.

References (4)
  1. (2023) "Product Information. Joenja (leniolisib)." Pharming Healthcare Inc.
  2. Bloomfield M, Klocperk A, Zachova R, Milota T, Kanderova V, Sediva A (2021) "Natural Course of Activated Phosphoinositide 3-Kinase Delta Syndrome in Childhood and Adolescence" Front Pediatr, 9, p. 1-12
  3. Rao KV, Dalm V, Sediva A (2023) Study of Efficacy of CDZ173 in Patients With APDS/PASLI https://clinicaltrials.gov/ct2/show/NCT02435173
  4. (2024) "Product Information. Joenja (leniolisib)." Pharming Technologies B.V.

Switch to consumer interaction data

Drug and food interactions

Moderate

leniolisib food

Applies to: leniolisib

MONITOR: Coadministration with inhibitors of CYP450 3A4 including grapefruit or grapefruit juice may increase the plasma concentrations of leniolisib, which undergoes extensive CYP450 3A4-mediated first-pass metabolism in the gut wall and liver. In general, the effect of grapefruit juice is concentration-, dose- and preparation-dependent, and can vary widely among brands. Certain preparations of grapefruit juice (e.g., high dose, double strength) have sometimes demonstrated potent inhibition of CYP450 3A4, while other preparations (e.g., low dose, single strength) have typically demonstrated moderate inhibition. Pharmacokinetic interactions involving grapefruit juice are also subject to a high degree of interpatient variability, thus the extent to which a given patient may be affected is difficult to predict.

MANAGEMENT: Patients who regularly consume grapefruit or grapefruit juice should be monitored for adverse effects and altered plasma concentrations of leniolisib. Some authorities recommend to avoid grapefruit products during leniolisib treatment (UK).

References (1)
  1. (2024) "Product Information. Joenja (leniolisib)." Pharming Technologies B.V.

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer